Is apremilast a promising treatment for psoriasis and psoriatic arthritis?

Introduction and objective: Apremilast (APR), is a small molecule that selectively inhibits the phosphodiesterase 4 (PDE-4) which modulates the release of pro- and antiinflammatory mediators. it was approved in February 2015 in Italy for the treatment of moderate-to-severe psoriasis and psoriatic arthritis (PsA) in adults. The aim of the authors is to assess the efficacy as well as the safety of the PDE-4 inhibitor apremilast both in PsA and psoriasis (Pso).